To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made: 13-Jul-16
Date of last disclosure: 23-Dec-16
Director or senior manager giving disclosure
Full name(s): Antony John Carter
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable): Not Applicable
Position held in listed issuer: Director
Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s): Beneficial interest in Ordinary
Shares
For that relevant interest-
Number held in class before acquisition : "(a) 4,947
(b) 65,552"
Number held in class after acquisition : "(a) 4,992
(b) 66,143"
Current registered holder(s): "(a) FNZ Custodians as custodians for Antony
Carter No 2 Family Trust;
(b) Loughborough Investments Limited - as Director of Company."
Registered holder(s) once transfers are registered:
Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative: Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Date of transaction: 23-Dec-15
Nature of transaction: "(a) Purchase of 45 Ordinary shares under the
Company''s dividend reinvestment plan.
(b) Purchase of 591 Ordinary shares under the Company''s dividend reinvestment
plan."
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration: "(a)
NZ$464.70
(b) NZ$6,103.02"
Number of financial products to which the transaction related: "(a) 45
(b) 591"
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period: No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period: Not Applicable
Date of the prior written clearance (if any): Not Applicable
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary Shares
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price''s specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made: 13-Jul-16
Date of last disclosure: 23-Dec-15
Director or senior manager giving disclosure
Full name(s): Arthur James MORRIS
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable): Not Applicable
Position held in listed issuer: Director
Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s): Beneficial interest in Ordinary
Shares
For that relevant interest-
Number held in class before acquisition: 9,154
Number held in class after acquisition: 9,236
Current registered holder(s): Niloc Trust (Family Trust)
Registered holder(s) once transfers are registered:
Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative: Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
Details of transactions giving rise to acquisition:
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction: 7-Jul-16
Nature of transaction: Purchase of 82 Ordinary shares under the Company''s
dividend reinvestment plan.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ$846.78
Number of financial products to which the transaction related: 82
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period: No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period: Not Applicable
Date of the prior written clearance (if any): Not Applicable
Summary of other relevant interests after acquisition :
Class of quoted financial products: Not applicable
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price''s specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made: 13-Jul-16
Date of last disclosure: 23-Dec-15
Director or senior manager giving disclosure
Full name(s): Donal Paul O''DWYER
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable): Not Applicable
Position held in listed issuer: Director
Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s): Beneficial interest in Ordinary
Shares
For that relevant interest-
Number held in class before acquisition: 55,614
Number held in class after acquisition: 56,153
Current registered holder(s): Donal Paul O''DWYER
Registered holder(s) once transfers are registered:
Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative: Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction: 7-Jul-16
Nature of transaction: Purchase of 539 Ordinary shares under the Company''s
dividend reinvestment plan.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ$5,566.04
Number of financial products to which the transaction related: 539
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period: No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period: Not Applicable
Date of the prior written clearance (if any): Not Applicable
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Not Applicable
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price''s specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made: 7-Jul-16
Date of last disclosure: 31-May-16
Director or senior manager giving disclosure
Full name(s): Scott Andrew ST JOHN
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer: Director
Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s): Beneficial interest in Ordinary
Shares
For that relevant interest-
Number held in class before acquisition or disposal: 12,074 Ordinary Shares
Number held in class after acquisition or disposal: 12,183 Ordinary Shares
Current registered holder(s): Scott Andrew ST JOHN
Registered holder(s) once transfers are registered:
Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative: Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction: 7-Jul-16
Nature of transaction:
Name of any other party or parties to the transaction (if known): Purchase
of 109 Ordinary Shares under the Company''s dividend reinvestment plan.
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:
NZ$1,125.60
Number of financial products to which the transaction related: 109
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period: No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period: Not Applicable
Date of the prior written clearance (if any): Not Applicable
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Not Applicable
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price''s specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
End CA:00285704 For:FPH Type:RELINT Time:2016-07-14 13:41:48